CD147:动脉粥样硬化治疗的新靶点?
DOI:
作者:
作者单位:

(江苏大学附属医院心血管内科,江苏省镇江市212008)

作者简介:

王寅宇,硕士研究生,研究方向为动脉粥样硬化,E-mail:Wangyy981002@163.com。通信作者王翠平,博士,副主任医师,硕士研究生导师,研究方向为动脉粥样硬化,E-mail:wangcuipingpeople@hotmail.com。

通讯作者:

基金项目:

江苏省卫生健康委基金项目(H2018004);江苏省青年医学重点人才培养基金项目(QNRC2016837)


CD147:a new target for atherosclerosis therapy?
Author:
Affiliation:

Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212008, China)

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    CD147是免疫球蛋白超家族成员,可在炎症组织中大量表达,具有促炎作用,而动脉粥样硬化作为一种慢性炎症性疾病,CD147的高表达促进动脉粥样硬化的机制已被大量研究证实,了解CD147如何促进动脉粥样硬化的发生发展可为该疾病的预防和治疗提供新的思路。同时,大量化合物被证实可通过下调CD147发挥抗动脉粥样硬化作用,为今后以CD147为靶标的药物设计提供了方向。本文综述了CD147致动脉粥样硬化的机制以及下调CD147的化合物的研究进展。

    Abstract:

    CD147 is a member of the immunoglobulin super family, which can be highly expressed in inflammatory tissues and has a pro-inflammatory effect. Atherosclerosis is well known as a chronic inflammatory disease, and the mechanism of high expression of CD147 promoting atherosclerosis has been confirmed by a large number of studies. Understanding how CD147 promotes the occurrence and development of atherosclerosis can provide new ideas for the prevention and treatment of this disease. At the same time, a large number of compounds have been proved to be able to downregulate CD147 to have anti-atherosclerosis effect, which also provides a direction for drug design targeting CD147 in the future. This article reviews the mechanism of atherosclerosis induced by CD147 and the research progress of compounds that downregulate CD147.

    参考文献
    相似文献
    引证文献
引用本文

王寅宇,王翠平. CD147:动脉粥样硬化治疗的新靶点?[J].中国动脉硬化杂志,2023,31(9):821~828.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2022-10-05
  • 最后修改日期:2022-11-20
  • 录用日期:
  • 在线发布日期: 2023-10-19